Vallon Pharmaceuticals Stock News

Vallon Pharmaceuticals (VLON) down as SEAL study evaluating lead investigational product candidate, ADAIR, fails to meet its primary endpoint.

Gainers Marygold Companies (NYSE: MGLD ) shares surged 89.4% to close at $4.11 on Friday after dropping 21% on Thursday. TeraWulf Inc. (NASDAQ: WULF ) gained 49.3% to close at $9.51. Guardforce AI Co., Limited (NASDAQ: GFAI ) jumped 45% to settle at $0.7796 after the company agreed to acquire Shenzhen Keweien and Guangzhou Kewei for $10 million. Clearside Biomedical, Inc. (NASDAQ: CLSD ) rose 42.6% to settle at $1.9250 after the company reported better-than-expected Q4 results. Excellon Resources Inc. (NYSE: EXN ) rose 40.8% to close at $1.38 after jumping around 13% on Thursday. Solid Biosciences Inc. (NASDAQ: SLDB ) jumped 37.4% to settle at $1.06. Altamira Therapeutics Ltd. (NASDAQ: CYTO ) shares gained 36.7% to settle at $0.9449. Altamira Therapeutics reported in vitro efficacy data for bentrio nasal spray in protecting against Sars-CoV-2 omicron variant. 4D pharma plc (NASDAQ: LBPS ) shares surged 35.3% to settle at $3.99. Kala Pharmaceuticals, Inc. (NASDAQ: KALA ) gained 33.1% to close at $1.69.

Gainers Imperial Petroleum Inc. (NASDAQ: IMPP ) jumped 63.1% to close at $0.80 on Tuesday after declining around 7% on Friday. Indonesia Energy Corporation Limited (NYSE: INDO ) shares surged 44.1% to close at $6.47 on Tuesday. Meritor, Inc. (NYSE: MTOR ) shares climbed 43.8% to settle at $35.47. Cummins Inc (NYSE: CMI ) agreed to acquire electric powertrain solutions provider Meritor for about $3.7 billion, including assumed debt and net of acquired cash. China Natural Resources, Inc. (NASDAQ: CHNR ) surged 27.4% to close at $0.7901. Paltalk, Inc. (NASDAQ: PALT ) rose 26.1% to close at $3.96. Ocugen, Inc. (NASDAQ: OCGN ) gained 22.3% to close at $4.23. The FDA has lifted its clinical hold on Ocugens investigational new drug application seeking approval to conduct testing of the COVID-19 vaccine Covaxin in the U.S. Arteris, Inc. (NASDAQ: AIP ) climbed 19% to close at $17.83. Arteris is expected release its financial results for the fourth quarter on Thursday, March 3, 2022. SeaChange International, Inc. (NYSE: SEAC ) rose 18.9% to settle at $1.26.

Vallon Pharmaceuticals press release (VLON): FY 2021 Net loss was $9.3M.Cash, cash equivalents and marketable securities of ~$7.5M

- T opline data for p ivotal abuse study of the C ompany’s lead investigational program ADAIR expected this quarter

– Liv e video webcast presentation on Tuesday, January 25 th at 9:00 AM ET

Vallon Pharmaceuticals Inc (VLON) shares closed this week 25.6% higher than it did at the end of last week. The stock is currently up 25.6% year-to-date, down 0.1% over the past 12 months, and down 0.1% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Shares traded as high as $8.40 and as low as $6.00 this week.Trading volume this week was 72.3% lower than the 10-day average and 85.3% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price beats the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -1708.3% The company's stock price performance over the past 12 months beats the peer average by -99.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

PHILADELPHIA, PA, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on th

- Topline results f ro m p ivotal SEAL study expected in Q1 2022

Vallon Pharmaceuticals, Inc. (NASDAQ:VLON) was the recipient of a significant growth in short interest during the month of November. As of November 30th, there was short interest totalling 727,400 shares, a growth of 496.7% from the November 15th total of 121,900 shares. Currently, 22.7% of the company’s stock are short sold. Based on an average […]

Vallon Pharmaceuticals, Inc. (NASDAQ:VLON) saw a large growth in short interest in the month of November. As of November 15th, there was short interest totalling 121,900 shares, a growth of 60.2% from the October 31st total of 76,100 shares. Approximately 3.8% of the companys shares are short sold. Based on an average daily trading volume, [] The post Short Interest in Vallon Pharmaceuticals, Inc. (NASDAQ:VLON) Grows By 60.2% appeared first on ETF Daily News .

Vallon Pharmaceuticals Inc. (NASDAQ:VLON) traded at $6.05 at close of the session on Monday, 11/29/21, made an upward move of 13.94% on its previous days price. Looking at the stock we see that its previous close was $5.31 with the days price range being $5.0501 $6.14. In terms of its 52-week price range, VLON Vallon Pharmaceuticals Inc. (NASDAQ: VLON) Analysts Revisions Show Sentiment Is Improving Read More »

Vallon Pharmaceuticals Inc (VLON) shares closed this week 23.6% higher than it did at the end of last week. The stock is currently down 28.3% year-to-date, down 28.3% over the past 12 months, and down 28.3% over the past five years. This week, the Dow Jones Industrial Average fell 0.2%, and the S&P 500 fell 0.1%. Trading Activity Shares traded as high as $8.54 and as low as $4.02 this week.Trading volume this week was 36.6% lower than the 10-day average and 99.8% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -7.4% The company's stock price performance over the past 12 months lags the peer average by 17.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

HC Wainwright began coverage on shares of Vallon Pharmaceuticals (NASDAQ:VLON) in a report issued on Monday, The Fly reports. The brokerage set a buy rating and a $12.00 price target on the stock. HC Wainwrights price objective points to a potential upside of 64.38% from the companys current price. Shares of NASDAQ VLON opened at []